Simpler Tool Promising for Atherosclerosis Prediction

Share this content:
Simpler Tool Promising for Atherosclerosis Prediction
Simpler Tool Promising for Atherosclerosis Prediction

THURSDAY, Nov. 16, 2017 (HealthDay News) -- The ideal cardiovascular health score (ICHS) and the Fuster-BEWAT (blood pressure, exercise, weight, alimentation, and tobacco) score (FBS) are similar in their ability to predict subclinical atherosclerosis, according to a study published online Nov. 13 in the Journal of the American College of Cardiology.

Juan Miguel Fernández-Alvira, Ph.D., from Centro Nacional de Investigaciones in Spain, and colleagues compared the effectiveness of ICHS and FBS in predicting the presence and extent of subclinical atherosclerosis among 3,983 participants (aged 40 to 54 years).

The researchers found that with poor ICHS and FBS as references, individuals with ideal ICHS and FBS showed lower adjusted odds of having atherosclerotic plaques (ICHS odds ratio [OR], 0.41; FBS OR, 0.49), coronary artery calcium (CACS) ≥1 (ICHS OR, 0.41; FBS OR, 0.53), higher number of affected territories (ICHS OR, 0.32; FBS OR, 0.39), and higher CACS level (ICHS OR, 0.4; FBS OR, 0.52). Similar levels of significantly discriminating accuracy were found for the ability of ICHS and FBS to predict the presence of plaques (C-statistic: 0.694 and 0.692, respectively) and CACS ≥1 (C-statistic: 0.782 and 0.78, respectively).

"Both scores predict the presence and extent of subclinical atherosclerosis with similar accuracy, highlighting the value of the FBS as a simpler and more affordable score for evaluating the risk of subclinical disease," conclude the authors.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »